Clinical Trials
9 trialsNCT00019760 2023-10-31
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00030082 2015-04-30
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089401 2012-05-14
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00019786 2012-03-23
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00020501 2012-03-08
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00001193 2008-03-04
A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001576 2008-03-04
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001587 2008-03-04
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
National Institutes of Health Clinical Center (CC)
Phase 1 Completed